Fampridine Study in Activities of Daily Living
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dalfampridine
Voltage-gated potassium channel blocker
What it measured
Main measures
Changes in gait mobility as assessed by GTX3+ accelerometers after 6 weeks
Walking and mobility
Other measures (1)
Changes in basic and instrumental activities of daily life as assessed by the COPM and
Who could take part
MS (type not specified)
Inclusion: Patients over 18 years with multiple sclerosis and an EDSS between 4 and 7, suffering from gait disturbance will be included. Only patients who have been identified as responders during a previous named patient programme and were refused to get reimbursement by the public health care system in Austria will be included. Exclusion: Exclusion criteria will be a treatment with Fampridine less then 6 weeks before the start of the study, previously identified non‐response to Fampridine and an age below 18 years.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of the study is to explore, if the use of Fampyra offers any meaningful improvement in the daily activity of patients as demanded from the public health care system in Austria.
Loading reviews and guidelines…
Related trials
- AmpPT
Phase 3 · Recruiting
Still running
- RESTORE
Phase 3 · Stopped early
Stopped: not working
- New strategies in neurological diseases
Phase 4 · Ongoing
Still running
- MUST
Not a drug-phase study · Completed
Result in a paper, not read yet
- FAMILY
Completed
Result in a paper, not read yet
- Fampridine Pregnancy Exposure Registry
Stopped early
Stopped early
History
Started
Aug 2015
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error